ADC Development Pipeline
By using all of the validated and proprietary technology platforms developed at NBE-Therapeutics, we have started to create an early preclinically validated portfolio of ADC product candidates.
In addition to ADCs against established and validated cancer targets, which are either out-licensed already (CD19 and HER-2) or potentially available for out-licensing (CD30), NBE-Therapeutics scientists have developed a preclinically validated portfolio of ADCs in four different cancer target programs, which address a wide variety of hematologic malignancies or solid tumors. Two lead programs are currently undergoing final lead optimization and characterization, and are expected to enter into IND-enabling development and cGMP manufacturing during Q1-2017. The current pipeline and status of NBE-Therapeutics' ADC development candidates is displayed below.
- Barcelona, 2017-05-18 - NBE-Therapeutics invited to present at the 2nd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics
- London, 2017-05-15 - NBE-Therapeutics will present at the 2nd Annual Advances in Immuno-Oncology Congress, London, U.K.
- Boston, MA, USA, 2017-05-02 - NBE-Therapeutics to present update on R&D activities at 2017-PEGS conference